PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00613119
First received: February 10, 2008
Last updated: April 15, 2014
Last verified: March 2014
  Purpose

This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal dementia (FTD), are associated with increased inflammation in the brain. This study may help elucidate the relationship between FTD and inflammation.

Patients with FTD and healthy volunteers who are 35 years of age or older may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood and urine tests.

Participants undergo the following procedures:

  • Whole body PET scan: PET uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is [11C]PBR28. Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer. Pictures are taken for 1 hour. This short scan is done to determine if [11C]PBR28 binds to the subject s receptors, since a number of people do not have binding. Subjects who have binding continue with brain PET and MRI scans, described below.
  • Brain PET imaging: Before starting the scan, a catheter is placed in a vein in the arm to inject the tracer,< TAB> and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. The subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. An 8-minute transmission scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans. After the tracer is injected, pictures are taken for about 2.5 hours, while the subject lies still on the scanner bed.
  • Blood and urine tests are done the day of and the day following each PET scan.
  • Magnetic resonance imaging (MRI): An MRI scan is done within 1 year (before or after) of the PET scan. This procedure uses a magnetic field and radio waves to produce images of the brain. The subject lies on a table that is moved into the scanner (a tube-like device), wearing earplugs to muffle the noise of the machine during the scanning process. The test takes about 1 hour.

Condition
Frontotemporal Lobar Degeneration
Dementia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Neurological Disorders

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Outcome measures will be the amount of [11C]PBR28 binding in the brain in FTD patients and in healthy controls.

Secondary Outcome Measures:
  • We will quantify the radioligand's brain uptake, washout, plasma clearance, and distribution volume using compartmental modeling.

Estimated Enrollment: 195
Study Start Date: January 2008
Detailed Description:

Objective:

Abnormal immune responses and inflammatory mechanisms have been implicated in the pathogenesis of certain neurodegenerative diseases. Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by focal atrophy of the frontal and temporal lobes. Evidence supports the presence of inflammation in FTD; however, the relationship between inflammation and FTD pathogenesis is poorly understood. In addition, there is evidence of inflammation in temporal lobe epilepsy (TLE), a condition characterized by seizures originating from the mesial temporal lobe.

In response to brain inflammation, microglia are activated and over-express the peripheral benzodiazepine receptor (PBR). In normal conditions, PBR is expressed in low numbers. Measuring PBR density can identify areas of brain inflammation, because activated microglial cells in these areas express more PBR than microglial cells in resting conditions. Positron emission tomography (PET) imaging can quantify PBR density in vivo using radioligands that bind to PBR sites. One PBR-specific radioligand, [11C]1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline carboxamide (PK11195), has been used to identify areas of brain inflammation in patients with FTD. Unfortunately, [11C]PK11195 has several limitations, such as low brain uptake and low specific signal. A recently developed radioligand, [11C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine (PBR28), has higher affinity than [11C]PK11195 for PBR. [11C]PBR28 has never been used to study inflammation in FTD.

To further study brain inflammation in dementia and TLE, we wish to include patients with Alzheimer disease (AD) and TLE.

Study population:

In this protocol, we wish to evaluate 20 patients with FTD, 50 100 patients with AD, 20 patients with TLE, and 30 55 healthy volunteers.

Design:

Subjects will undergo a dedicated brain PET with [11C]PBR28, as well as a brain MRI. In AD patients and controls, 11C PBR28 PET and MRI will then be repeated after an interval of one year but no more than 5 years.

Outcome measures:

Outcome measures will be the amount of 11C PBR28 binding in the brain in FTD patients, AD patients, TLE patients and in healthy controls. We will quantify the radioligand s brain uptake, washout, plasma clearance, and distribution volume using compartmental modeling. Distribution volume is proportional to the density of receptors and is equal to the ratio at equilibrium of uptake in brain to the concentration of parent radiotracer in plasma. 11C PBR28 binding will also be compared between baseline and follow-up scans to determine the change in binding related to evolution of AD pathology and that related to normal aging.

  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:
  • Patients with a diagnosis of Alzheimer disease or frontotemporal dementia (FTD). FTD patients with or without motor involvement may be included. FTD patients with either the frontal variant (also known as the behavioral variant) or the language variant of FTD may be included. AD and FTD patients must either meet capacity criteria to consent to research, or be able to assign a surrogate decision-maker who is able to consent to research on the subject s behalf.
  • TLE patients must have clinically documented partial seizures with consistent EEG evidence as defined by the 1981 International Classification of Epileptic Seizures, refractory to standard antiepileptic treatment for at least one year. This criterion will be established by preliminary screening in the NINDS Clinical Epilepsy Section outpatient clinic, and if necessary, inpatient video-EEG monitoring.
  • Healthy volunteers.

EXCLUSION CRITERIA:

  • Current psychiatric disease, substance abuse or severe systemic disease based on history and physical exam.
  • Laboratory tests with clinically significant abnormalities.
  • Prior participation in other research protocols or clinical care in the last year such that radiation exposure, including that from this protocol, would exceed the guidelines set by the Radiation Safety Committee (RSC).
  • Pregnancy or breast feeding.
  • Positive result on urine screen for illicit drugs.
  • Subjects who cannot lie on their back for extended periods of time.
  • History of neurological disease other than FTD or AD or TLE.
  • TLE patients:

    1. with a known treatable seizure etiology such as neoplastic or infectious disease
    2. with an MRI finding consistent with a brain tumor, trauma or arterial-venous malformations
    3. with seizure activity within 24 hours prior to the study.
    4. not capable of giving an informed consent.
  • Presence of ferromagnetic metal in the body or heart pacemaker.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00613119

Contacts
Contact: Emily M Page, C.R.N.P. (301) 451-7904 emily.page@nih.gov
Contact: Robert B Innis, M.D. (301) 594-1368 robert.innis@nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: Robert B Innis, M.D. National Institute of Mental Health (NIMH)
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00613119     History of Changes
Other Study ID Numbers: 080066, 08-M-0066
Study First Received: February 10, 2008
Last Updated: April 15, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Inflammation
Frontotemporal Dementia
Dementia
PBR28
PET Imaging

Additional relevant MeSH terms:
Speech Disorders
Dementia
Nervous System Diseases
Frontotemporal Dementia
Aphasia, Primary Progressive
Pick Disease of the Brain
Frontotemporal Lobar Degeneration
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
TDP-43 Proteinopathies
Neurodegenerative Diseases
Proteostasis Deficiencies
Metabolic Diseases
Aphasia
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on August 21, 2014